A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

Trial Profile

A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine
  • Indications Biliary cancer; Bladder cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NanoCarrier
  • Most Recent Events

    • 05 Apr 2017 Planned number of patients changed from 160 to 182.
    • 05 Apr 2017 Planned End Date changed from 1 May 2018 to 1 Nov 2017.
    • 05 Apr 2017 Planned primary completion date changed from 1 May 2018 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top